Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 204-317-7
CAS number: 119-36-8
Genotoxicity in vitro:
In a reverse gene mutation assay (Ames test) in bacteria (Mortelmans,
1986), Salmonella typhimurium strains TA1535, 1537, 98 and 100 were
exposed to methyl salicylate, at concentrations of 1.0 to 333.3 µg/plate
with and without metabolic activation by S9 fraction from the livers of
male rats and hamsters. Cytotoxicity was evident at the highest
concentration. There was no evidence of induced mutant colonies over
background either with or without metabolic activation in any tested
strain. In a reverse gene mutation assay (Ishidate et al, 1984),
Salmonella typhimurium strains TA 92, 94, 98, 100, 1535 and 1537 were
exposed to MeS with and without metabolic activation by liver microsomal
fraction, S9, from Fischer rats pretreated with polychlorinated
biphenyls. Methyl salicylate was non-mutagenic under the assay
conditions. It is concluded that MeS is not mutagenic in bacteria.
In a mammalian cell chromosome aberration assay (Ishidate et al.,
1984),cell cultures were exposed to MeS at three concentrations up to
0.25 mg/ml for 24 or 48 hours without metabolic activation. The
cytotoxic concentration was defined as the dose which induced 50% cell
growth inhibition. Methyl salicylic acid did not induce a clastogenic
effect. No positive controls were reported. In a mammalian cell
cytogenetics assay for chromosome aberration (Stich et al., 1981), CHO
cell cultures were exposed to the hydrolysis product SA at concentration
of 25 mg/ml for 3 hours with and without metabolic activation. The
concentration used was half the dose which induced mitotic inhibition,
defined as one metaphase or less in 6000 CHO cells. In addition, CHO
cells were exposed to 12 mg/ml of Salicylic acid with a transition metal
10-4M)without a metabolic activation. Salicylic acid
did not induce a clastogenic effect.
In a Rel. 1 mouse lymphoma L5178Y study (Wollny, 2008), SA was tested at
87.5, 175.0, 350.0, 1400.0 µg/ml. The first experiment was performed
with and without liver microsomal activation and a treatment period of 4
h. The second experiment was solely performed in the absence of
metabolic activation with a treatment period of 24 hours. Relevant
cytotoxic effects were solely noted following 24 h treatment in the
second experiment at 700 µg/ml and above. No substantial and
reproducible dose dependent increase in mutant colony numbers was
observed in both main experiments. No relevant shift of the ratio of
small versus large colonies was observed up to the maximal
concentration. SA was considered to be non-mutagenic in this mouse
Genotoxicity in vivo:
No in vivostudies have been
carried out on MeS itself, however data are available from the
read-across substance SA.
Two in vivochromosome aberrations
on SA have been published by Giri et al. (1996). In the first study,
Swiss albino male mice were treated with SA dissolved in DMSO (75
µl/mouse), in an i.p. administration at the doses of 50, 100 and 200
mg/kg. Four mice were used for each dose along with a negative control.
Negative control mice received equal volume of only DMSO. Five mice were
injected cyclophosphamide (25 mg/kg) in equal volume of DMSO (75
µl/mouse) and served as positive control. No significant increase in CA
was observed for SA when compared with solvent control. A significant
increase in MI was observed at the lowest dose for SA. Positive control
chemical cyclophosphamide induced high chromosome aberrations over
solvent control. In the second study, Swiss albino male mice were
treated with SA suspended with 2% gum acacia in distilled water (0.3
ml/mouse), by gavage at the dose of 350 mg/kg. Five mice were used for
treated group along with a negative control. Negative control mice were
gavaged with 2% gum acacia in distilled water. No significant increase
in CA was observed for SA when compared with solvent control. A
significant increase in MI was observed for SA. Positive control
chemical cyclophosphamide induced high chromosome aberrations over
solvent control. Although each for these key studies had minor
deviations from current guidelines, taken together they are considered
The publication by Giri et al (1996)
also reports twoin vivosister chromatid exchange assays. In the
first study, Swiss albino male mice were treated with SA in DMSO (75
µl/mouse) in a single i.p. injection at the dose of 25, 50 and 100
mg/kg. Negative control mice were injected with 75 µl DMSO while
mitomycin C was used as a positive control at a dose of 1.5 mg/kg bw. No
significant increase in SCE was observed for SA when compared with
solvent control. Positive control chemical mitomycin C gave a very high
frequency of SCE over those of solvent control. In the second study,
Swiss albino male mice were treated with SA suspended in distilled water
in 2 % gum acacia (0.3 ml/mouse), in a single oral administration at the
dose of 350 mg/kg. Negative control mice were administered with gum
acacia. No positive control was used. No significant increase in SCE was
observed for SA when compared with solvent control. Taken together,
these studies are acceptable.
MeS did not show any mutagenicity in
bacteria (S. typhimurium) or in mammalian cells and did not cause
structural chromosome aberrations in CHO cells, fromin vitrostudies.
Its hydrolysis product SA did not induce either chromosome aberrations
or sister chromatid exchanges in i.p. or oral studiesin vivoin
mice, indicating that SA is not genotoxic in the bone marrow cells of
mice. Taken together, these results indicate that MeS is not genotoxic.
Short description of key information:
The genotoxic potential of MeS has been evaluated from in vitro studies on MeS itself and from in vitro and in vivo studies on the read-across substance salicylic acid, the initial metabolite by hydrolysis of MeS. All tests gave negative results, leading to the conclusion that MeS is not genotoxic. For in vitro gene mutation studies in bacteria, two publications (Rel. 2) describing Ames tests in various strains of S. typhimurium have been chosen as Key studies, Mertelmans (1986) and Ishidate (1984). For in vitro mammalian cell gene mutation, a study on SA (RCC, 2008) performed according to OECD guideline 476 (Rel 1) has been chosen as key study. For chromosomal aberration in mammalian cells in vitro, a publication (Rel. 2) by Ishidate (1984) has been chosen as key study, with another, on SA, by Stich et al. (1981) (Rel. 2) as supporting study. For genotoxicity in vivo, a publication by Giri et al. (1996) describing oral and intraperitoneal studies on chromosome aberrations and sister chromatid exchange in the bone marrow cells of mice on SA has been taken as key study.
Endpoint Conclusion: No adverse effect observed (negative)
Not genotoxic according to EU and GHS (UN/EU) criteria.
Based on absence of mutagenicity in
bacterial or mammalian cells, absence of clastogenicity in chromosome
aberration studiesin vitroand absence of induction of either
chromosome aberrations or sister chromatid exchangesin vivoin
mice, from studies on MeS and hydrolysis product SA. These results
indicate that MeS is not genotoxic.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Siekdami užtikrinti, kad būtų patogu naudotis mūsų svetaine, jos tinklapiuose naudojame slapukus.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again